Opioid Receptors in Human Neoplasms: Growth Hormone and Prolactin Response to Morphine,Met-Enkephalin and Buprenorphine in Cancer Patients

Abstract

Get full access to this article

View all access options for this article.

References

Vinnitsky

V.B.

Neurohumoral mechanisms of the formation of antitumor activity.

N Y Acad Sci 1988; 521: 195–214.

Viviani

, Santoro

, Ragni

, Bonfante

, Bestetti

, Bonadonna

Gonadal toxicity after combination for Hodgkin's disease. Comparative results of MOPP vs ABVD.

Eur J Cancer Clin Oncol 1985; 21: 601–5.

Barni

, Lissoni

, Rovelli

. Alteration of opioid peptide circadian rhythm in cancer patients. Tumori 1988; 74: 357–60.

Mathews

P.M.

, Froelich

C.J.

, Sibbitt

W.L.

, Bankurst

A.D.

Enhancement of natural cytotoxicity by beta-endorphin.

J Immunol 1983; 130: 1658–62.

Morley

J.E.

, Kay

, Allen

, Moon

, Billington

C.J.

Endorphins, immune function, and cancer.

Psychopharmacol Bull 1985; 21: 485–8.

Quigley

M.E.

, Sheehan

K.L.

, Casper

R.F.

, Yen

S.S.C.

Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma.

J Clin Endocrinol Metab 1980; 50: 427–31.